---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-015307"
form_type: "8-K/A"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:26:58.045930+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics amends 8-K to correct Cullgen stock conversion terms in $300M acquisition

## Summary
- Amendment fixes clerical error in original March 2, 2026 8-K describing stock conversion for Cullgen holders.
- Designated Cullgen shareholders receive Series B Convertible Preferred, convertible into 5 Gyre common shares each.
- Other Cullgen holders receive Gyre common stock at exchange ratio of 0.4753 per Cullgen share.
- All-stock deal values Cullgen at ~$300 million; no substantive changes to merger agreement beyond correction.

## SEC filing metadata
- accession: 0001140361-26-015307
- form_type: 8-K/A
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036126015307/0001140361-26-015307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036126015307/ef20070667_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-015307
- JSON: https://secwatch.observer/filing/0001140361-26-015307.json
- Plain text: https://secwatch.observer/filing/0001140361-26-015307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.